US EditionPublished • loading... • Updated
Advanced Head and Neck Squamous Cell Carcinoma Patients Double Survival Time – Patient Worthy
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Advanced Head and Neck Squamous Cell Carcinoma Patients Double Survival Time – Patient Worthy
Health Canada’s recent approval of adjuvant (applied after surgery) Keytruda (pembrolizumab) in high-risk invasive cancer of the bladder saw patients remain free of cancer in double the current standard, according to Cancer Network. Overview A study found that adjuvant Keytruda to treat high-risk, muscle-invasive bladder cancer increased the median time patients remained cancer-free after surgery. […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
